• 1
    2002 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1989–2001. Rockville MD : HHS/HRSA/OSP/DOT and UNOS
  • 2
    Gaston RS, Danovitch GM, Adams PL et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3: 775785.DOI: 10.1034/j.1600-6143.2003.00146.x
  • 3
    Knoll GA, Tankersley MR, Lee JY, Julian BA Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608614.
  • 4
    Pereira BJ, Natov SN, Bouthot BA et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53(5): 13741381.DOI: 10.1046/j.1523-1755.1998.00883.x
  • 5
    Pereira BJ Levey AS, Hepatitis C infection in cadaver organ donors: Strategies to reduce transmission of infection and prevent organ waste. Pediatr Nephrol, 1995; 9 Suppl: S2328.DOI: 10.1007/BF00867679
  • 6
    Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843861.
  • 7
    Navasa M, Bustamante J, Marroni C et al. Diabetes mellitus after liver transplantation: Prevalence and predictive factors. J Hepatol 1996; 25: 6471.DOI: 10.1016/S0168-8278(96)80329-1
  • 8
    Hanafusa T, Ichikawa Y, Kishikawa H et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471476.DOI: 10.1097/00007890-199808270-00010
  • 9
    Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257263.DOI: 10.1002/hep.510290123
  • 10
    Van Duijnhoven E, Boots J, Christiaans M, Wolffenbuttel B Van Hooff J. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 583588.
  • 11
    Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 32703277.DOI: 10.1097/01.ASN.0000100127.54107.57
  • 12
    Pereira BJ, Wright TL, Schmid CH Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799805.
  • 13
    Krentz AJ, Dousset B, Mayer D et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes 1993; 42: 17531759.
  • 14
    Tamura K, Fujimura T, Tsutsumi T et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic β-cell. Transplantation, 1995. 59: 16061613.
  • 15
    Margreiter R. A prospective, randomized multicentre study to compare the efficacy and safety of tacrolimus and cyclosporin microemulsion in renal transplantation. Transplantation 2000; 69: 112.
  • 16
    Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 13741380.
  • 17
    Yildiz A, Tutuncu Y, Yazici H et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation 2002; 74: 11091113.DOI: 10.1097/00007890-200210270-00009
  • 18
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178185.DOI: 10.1034/j.1600-6143.2003.00010.x
  • 19
    The French METAVIR Collaborative Study. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20 (1 pt 1): 1520.DOI: 10.1016/0270-9139(94)90128-7
  • 20
    Martin P, Carter D, Fabrizi F et al. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69: 14791484.DOI: 10.1097/00007890-200004150-00045
  • 21
    Sterling RK, Sanyal AJ, Luketic VA et al. Chronic hepatitis C infection in patients with end stage renal disease: Characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 35763582.DOI: 10.1016/S0002-9270(99)00708-X
    Direct Link:
  • 22
    Meyers CM, Seeff LB, Stehman-Breen CO Hoofnagle JH. Hepatitis C and renal disease: An update. Am J Kidney Dis 2003; 42: 631657.DOI: 10.1016/S0272-6386(03)00828-X
  • 23
    Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629634.
  • 24
    Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592599.
  • 25
    Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 16951704.
  • 26
    Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 13841392.
  • 27
    Roth D, Reddy R, Kupin W et al. Long-term impact of HCV on clinical outcomes and liver histology in kidney recipients [Abstract]. Am J Transplant 2004; 4 (Suppl 8): 289.
  • 28
    Woodward RS, Schnitzler MA, Baty J et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590598.DOI: 10.1034/j.1600-6143.2003.00082.x